Loading…
← CockpitCompetitor Analysis › COGT Cogent Biosciences, Inc.Open in the cockpit ↗

Cogent Biosciences, Inc.COGTCompetitor analysis, valuation and peers

United States · USD·Health Care›Biotechnology

Biotech developing bezuclastinib, a precision KIT-inhibitor drug for systemic mastocytosis and gastrointestinal stromal tumors.

Momentum weak 28
Mkt cap
$4.84B
US dollars, full cap
Free float
90%
of shares outstanding
$/day
$64.6M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
n/a
WACC 6.8%
Hurdle
n/a
no reverse DCF
Next earnings
118 days
16 Mar 2027
Close · USD$27.81
1D-0.1%
1W-5.4%
1M-11.0%
3M-21.2%
6M-15.5%
YTD-21.7%
1Y-17.6%
ATR %5.8%
Beta1.33
52w lowhigh36.4% off high

What Cogent Biosciences does

Biotech developing bezuclastinib, a precision KIT-inhibitor drug for systemic mastocytosis and gastrointestinal stromal tumors.

Has no product to sell yet, so spending is funded by investors' money rather than customers. Everything rests on one drug, bezuclastinib, in trials for a rare blood-cell disorder, systemic mastocytosis, and for gastrointestinal stromal tumors, and on the regulatory decisions that follow.

Products and services

  • Bezuclastinib (systemic mastocytosis, GIST, pipeline)

Customers

  • Hematologists/oncologists treating mastocytosis an

Where it sits in the supply chain

  • Healthcare
  • Biotechnology
  • Precision oncology/rare disease drug…

What could go right

  • Approval and launch in mastocytosis/GIST niches
  • Differentiated efficacy/safety versus Blueprint's Ayvakit

What could go wrong

  • Pre-revenue, binary late-stage trial risk
  • An established competitor already on market

Moat: narrow (IP / patents). A selective KIT D816V inhibitor with a differentiated safety profile versus approved competitors in a niche rare-disease market.

Headquarters: Cambridge, Massachusetts, US · Founded: 2016 · Employees: 258

Named competitors

Cogent Biosciences at a glance

Size Cogent Biosciences (COGT) is a United States Health Care company (Biotechnology) with a market value of $4.84B, the 1196th largest of 3,085 United States companies the cockpit tracks. Shares closed at $27.81 on 18 Nov 2026.

Performance Over six months the shares fell 15.5%, against +1.5% for the median peer and -2.2% for the United States market (cap-weighted) — 5th lowest of 21 in its peer set.

Credit Cogent Biosciences has 1 bond outstanding ($230M).

Short interest Short interest is 10.0% of the free float (30 Oct 2026).

Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 101COGT 85
Six months, rebased to 100: Cogent Biosciences against the median of its 20 peers (local-currency closes).

Cogent Biosciences financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$0$0$0$0$0
Revenue growth—————
Gross profit-$4.95M-$4.62M-$4.40M-$3.59M-$5.88M
EBITDA-$418M-$329M-$272M-$205M-$142M
Net income-$408M-$329M-$256M-$192M-$140M
Free cash flow-$326M-$266M-$208M-$156M-$126M
Capital expenditure$1.74M$1.55M$573,000$2.80M$6.86M
Total debt$244M$239M$17.5M$18.9M$19.6M

Quarterly statements and history in the cockpit →

Cogent Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%300347DNTHADPT002252EWTX0006613001221530ANTHEM603392CAISRRK6696CRSPARWRTNGX6127KODRLAYABCLCOGT6-month return →1-month return →
Up and to the right = strong over both horizons. Cogent Biosciences is the large dot.

Cogent Biosciences competitors and peer comparison

Head to head with its named competitors (COGT vs NOVN.SW vs SAN.PA vs 4528.T)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Cogent Biosciences COGT$4.84B-16%n/an/an/an/a
Novartis NOVN.SW$285B+11%-4%30%6.2×1.6%
Sanofi SAN.PA$114B+13%+15%27%2.6×-4.8%
ONO Pharmaceutical 4528.T$7.33B-2%-2%22%2.1×-6.8%

How Cogent Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Cogent Biosciences against its 20 peers (data as of 18 Nov 2026)
MeasureCOGTPeer medianRank in peer set
1-month return-11.0%-5.3%8th lowest of 21
6-month return-15.5%+1.5%5th lowest of 21
Distance from 52-week high-36.4%-31.9%7th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Cogent Biosciences COGTUnited States$4.84B-16%n/an/an/an/an/a
Hangzhou Tigermed Consulting 300347.SZChina$4.88B-2%+16%10%4.8×25.9%+16.4%
Dianthus Therapeutics DNTHUnited States$4.73B-5%-12%-8,684%1,432.1×n/an/a
Adaptive Biotechnologies ADPTUnited States$4.61B+104%+18%-16%15.8×n/an/a
Shanghai RAAS Blood Products 002252.SZChina$4.57B-15%-22%17%5.4×n/an/a
Edgewise Therapeutics EWTXUnited States$4.53B+26%n/an/an/an/an/a
Changchun High-Tech Industry (Group) 000661.SZChina$4.52B-13%-18%-1%2.8×32.4%+7.1%
Chongqing Zhifei Biological Products 300122.SZChina$5.28B-1%-28%-210%5.3×-6.5%-10.0%
3SBio 1530.HKHong Kong$4.28B-31%+102%61%0.9×n/an/a
Anthem Biosciences ANTHEM.NSIndia$5.51B+16%-1%35%24.9×36.9%+26.2%
Beijing Wantai Biological Pharmacy Enterprise 603392.SSChina$4.20B-43%+8%-35%12.7×n/an/a
Caris Life Sciences CAIUnited States$5.59B+24%+61%13%5.0×18.2%+61.5%
Scholar Rock SRRKUnited States$5.86B-1%n/a-71,732%9,900.4×n/an/a
Lin BioScience 6696.TWOTaiwan$3.98B+305%n/an/an/an/an/a
CRISPR Therapeutics CRSPUnited States$3.90B-17%-34%-2,059%95.6×n/an/a
Arrowhead Pharmaceuticals ARWRUnited States$6.09B-44%-46%-157%14.0×n/an/a
Tango Therapeutics TNGXUnited States$3.71B+4%-100%n/an/an/an/a
JOINN Laboratories (China) 6127.HKHong Kong$3.70B+6%+17%-4%12.4×n/an/a
Kodiak Sciences KODUnited States$6.40B+170%n/an/an/an/an/a
Relay Therapeutics RLAYUnited States$3.65B+27%+24%-3,095%273.1×n/an/a
AbCellera Biologics ABCLUnited States$3.60B+141%+92%-298%43.4×n/an/a

Cogent Biosciences bonds and credit

Cogent Biosciences has 1 bond outstanding with $230M face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Cogent Biosciences's main competitors?
Named competitors: Blueprint Medicines (Ayvakit) (private or unlisted), Novartis (Gleevec, in GIST) (NOVN.SW), Sanofi (SAN.PA), Ono Pharmaceutical (4528.T). The cockpit's measured peer set (industry) also includes Hangzhou Tigermed Consulting (300347.SZ), Dianthus Therapeutics (DNTH), Adaptive Biotechnologies (ADPT), Shanghai RAAS Blood Products (002252.SZ), Edgewise Therapeutics (EWTX), Changchun High-Tech Industry (Group) (000661.SZ).
How has Cogent Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned -15.5% against +1.5% for the median peer; over one year -17.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.